Actively Recruiting
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Led by Anhui Provincial Hospital · Updated on 2024-12-18
30
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell transplantation
CONDITIONS
Official Title
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT)
- Age between 14 and 60 years, any gender or ethnicity
- ECOG performance status score of 2 or less
- Presence of HLA-class I or class II antibodies with MFI 5000 or higher within 1 month before transplantation
- No severe organ failure and no active infections
- Willingness of patients and their families to undergo anti-HLA antibody testing and desensitisation treatment and to provide informed consent
You will not qualify if you...
- Severe disease or dysfunction of the heart, liver, kidneys, or pancreas
- Pregnancy
- Refusal by patient or authorized family members to accept antibody desensitisation treatment
- Any life-threatening disease or organ dysfunction that may risk patient safety or study results as judged by the investigator
- Drug dependence, uncontrolled psychiatric disorders, or cognitive dysfunction
- Participation in another clinical study within the past 3 months
- Investigator judgment of unsuitability for enrollment due to inability to adhere to examinations or treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, Anhui, China, 230036
Actively Recruiting
Research Team
X
Xiaoyu Zhu, ph.D.
CONTACT
Y
Yue Wu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here